Mesirow Financial Investment Management Inc. Buys Shares of 16,350 Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Mesirow Financial Investment Management Inc. purchased a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 16,350 shares of the company’s stock, valued at approximately $372,000.

Several other hedge funds have also made changes to their positions in VRDN. Novo Holdings A S grew its stake in shares of Viridian Therapeutics by 81.8% in the second quarter. Novo Holdings A S now owns 2,000,000 shares of the company’s stock worth $26,020,000 after purchasing an additional 900,000 shares in the last quarter. Maverick Capital Ltd. grew its position in Viridian Therapeutics by 22.9% in the 2nd quarter. Maverick Capital Ltd. now owns 3,307,945 shares of the company’s stock valued at $43,036,000 after buying an additional 615,531 shares in the last quarter. Candriam S.C.A. increased its stake in Viridian Therapeutics by 167.8% during the 2nd quarter. Candriam S.C.A. now owns 749,804 shares of the company’s stock valued at $9,754,000 after buying an additional 469,804 shares during the period. Vanguard Group Inc. raised its position in shares of Viridian Therapeutics by 7.8% during the 1st quarter. Vanguard Group Inc. now owns 3,234,279 shares of the company’s stock worth $56,632,000 after buying an additional 233,331 shares in the last quarter. Finally, Millennium Management LLC lifted its stake in shares of Viridian Therapeutics by 1,014.7% in the 2nd quarter. Millennium Management LLC now owns 228,182 shares of the company’s stock worth $2,969,000 after acquiring an additional 207,711 shares during the period.

Insider Activity at Viridian Therapeutics

In other Viridian Therapeutics news, COO Thomas W. Beetham acquired 5,000 shares of the firm’s stock in a transaction on Friday, September 27th. The stock was purchased at an average cost of $23.41 per share, for a total transaction of $117,050.00. Following the transaction, the chief operating officer now owns 6,000 shares of the company’s stock, valued at $140,460. The trade was a 500.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, COO Thomas W. Beetham bought 5,000 shares of the stock in a transaction on Friday, September 27th. The shares were purchased at an average price of $23.41 per share, for a total transaction of $117,050.00. Following the completion of the purchase, the chief operating officer now directly owns 6,000 shares of the company’s stock, valued at $140,460. This trade represents a 500.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Stephen F. Mahoney bought 21,400 shares of the company’s stock in a transaction on Friday, September 27th. The stock was purchased at an average cost of $23.33 per share, for a total transaction of $499,262.00. Following the completion of the transaction, the chief executive officer now owns 21,400 shares in the company, valued at approximately $499,262. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 1,626,400 shares of company stock valued at $30,616,312. Company insiders own 0.65% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. The Goldman Sachs Group raised their price objective on shares of Viridian Therapeutics from $25.00 to $31.00 and gave the company a “buy” rating in a research note on Thursday, September 12th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $44.00 target price on shares of Viridian Therapeutics in a research note on Thursday, September 19th. Oppenheimer reaffirmed an “outperform” rating and set a $28.00 target price (down from $31.00) on shares of Viridian Therapeutics in a report on Monday, August 12th. Wedbush reissued an “outperform” rating and issued a $42.00 price target on shares of Viridian Therapeutics in a report on Monday, July 29th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Viridian Therapeutics in a research note on Tuesday, September 10th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $35.80.

Viridian Therapeutics Price Performance

VRDN opened at $22.43 on Wednesday. The firm has a market capitalization of $1.43 billion, a P/E ratio of -5.33 and a beta of 1.10. The stock has a fifty day moving average of $22.04 and a 200-day moving average of $16.78. The company has a quick ratio of 15.82, a current ratio of 15.82 and a debt-to-equity ratio of 0.05. Viridian Therapeutics, Inc. has a 12-month low of $11.40 and a 12-month high of $27.20.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.